Search Results for "actemra"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for actemra. Results 11 to 14 of 14 total matches.
See also: tocilizumab

Sarilumab (Kevzara) for Polymyalgia Rheumatica

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
inhibitor tocilizumab (Actemra) and the CD20 inhibitor rituximab (Rituxan, and biosimilars) have also ...
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. Sarilumab is the first biologic drug to be approved for treatment of PMR; it was previously approved for treatment of rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8   doi:10.58347/tml.2024.1702c |  Show IntroductionHide Introduction

Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
. CRS has been successfully treated with the IL-6 receptor antagonist tocilizumab (Actemra ...
The FDA has approved idecabtagene vicleucel (Abecma – BMS), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Abecma is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Ciltacabtagene autoleucel...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e190-1 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
weeks 3206.80 (Sanofi/Regeneron) pens and syringes Tocilizumab8 – Actemra 80, 200, 400 mg single-dose ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
has been successfully treated with the IL-6 receptor antagonist tocilizumab (Actemra), with or without corticosteroids ...
The FDA has approved ciltacabtagene autoleucel (Carvykti – Janssen), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Carvykti is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Idecabtagene...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e188-9 |  Show IntroductionHide Introduction